Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vactosertib - MedPacto

Next Previous
Drug Profile

Vactosertib - MedPacto

Alternative Names: EW-7197; NOV 1301; TEW-7197

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ewha Womans University
  • Developer AstraZeneca; Case Comprehensive Cancer Center; MedPacto; Merck & Co; National OncoVenture; Samsung Medical Center; Yonsei University Health System
  • Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Pancreatic cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Colorectal cancer
  • Phase II Bladder cancer; Fibroma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Myelodysplastic syndromes; Osteosarcoma
  • No development reported Solid tumours

Most Recent Events

  • 09 Dec 2024 MedPacto withdraws the phase-II clinical trials in Fibroma (Combination therapy, Late-stage disease) in South Korea (PO) due to changing trial strategy (NCT06219733)
  • 04 Dec 2024 MedPacto terminates a phase II trial for Non-small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in South Korea (PO, Tablet), because Medpacto decided to modify its development strategy as the business and development environment changed (NCT04515979)
  • 04 Dec 2024 MedPacto withdraws a phase II trial prior to patient enrollment for Urogenital cancer (Combination therapy, Late-stage disease, Second-line therapy or greater), due to a change in trial strategy (NCT04064190)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top